source
- ai3Bio raises $48 million to develop T-cell targeting therapy for autoimmune diseaseai3Bio announced its emergence from stealth mode after securing $48 million in Series A funding. The round was led by UPMC Enterprises and Ziff Capital Partners and combines technology from Corner…
- Merck licenses KRAS G12D inhibitor from Tao Hu for $400 million upfrontMerck has signed a licensing agreement for a KRAS G12D inhibitor, providing an upfront payment of $400 million. The deal follows a 2023 transaction in which the same entrepreneur, synthetic chemis…